Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR mutation + MET amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR mutation + MET amplification	Non Small Cell Lung Cancer	EGFR mutation + MET amplification	Non Small Cell Lung Cancer	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3	erlotinib Sensitive: C3 – Early Trials erlotinib Sensitive : C3
EGFR mutation + MET amplification	Non Small Cell Lung Cancer	EGFR mutation + MET amplification	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR mutation + MET amplification	Non Small Cell Lung Cancer	EGFR mutation + MET amplification	Non Small Cell Lung Cancer	osimertinib + SCC244 Sensitive: C3 – Early Trials osimertinib + SCC244 Sensitive : C3	osimertinib + SCC244 Sensitive: C3 – Early Trials osimertinib + SCC244 Sensitive : C3